New Study: Popular Weight-Loss Drugs Linked to 30% Spike in ‘Silent’ Health Risk

Roughly 1 in 8 Americans have reported using some kind of GLP-1 drug. That’s approximately 12% of the adult population of the United States. They have started to rely on GLP‑1 medications like Ozempic, Wegovy, and Mounjaro for weight loss, diabetes management, and even potential cognitive and cardiovascular benefits. A new study released this week is raising some red flags about long-term use of these drugs, though.

There has been a 30% spike in a certain health risk among people who have used these drugs for an extended period of time. So, if you are taking any kind of GLP-1, it’s important to be aware of this. Here’s what you need to know.

What Exactly Did the New Study Reveal About Bone Health?

Researchers found that 4% of GLP‑1 users with obesity and Type 2 diabetes developed osteoporosis, compared with just over 3% of non‑users, which is a roughly 30% increased risk. Osteoporosis is a condition marked by low bone mineral density, making bones fragile and more prone to fractures. The study also found that osteomalacia, a condition where bones soften, occurred twice as often among GLP‑1 users.

Lead author Dr. John Horneff noted that the risk of bone‑density issues nearly doubled after five years of use. While the study was observational and didn’t account for diet or exercise, the findings align with earlier research linking GLP‑1 side effects to bone‑related complications.

Why Might GLP‑1 Drugs Increase the Risk of Osteoporosis?

GLP‑1 medications suppress appetite, which can unintentionally reduce intake of essential nutrients like calcium and vitamin D. These nutrients are critical for maintaining strong bones, especially as people age. Rapid weight loss (common with GLP‑1 drugs) can also accelerate bone loss, similar to what astronauts experience in low‑gravity environments.

Dr. Horneff explained that when the body suddenly carries less weight, bones receive fewer mechanical signals to stay strong. This combination of reduced nutrients and decreased skeletal load may contribute to these GLP‑1 side effects.

Why Are Women in Midlife Especially Vulnerable?

Women in perimenopause and menopause naturally experience declining estrogen levels, a hormone essential for bone remodeling. When estrogen drops, bone loss speeds up, making fractures more likely.

Adding GLP‑1 side effects like nutrient deficiencies or rapid weight loss can compound this vulnerability. The study suggests that women in this age group may face a higher risk of osteoporosis when using these medications. This makes bone‑health monitoring even more important for midlife women taking GLP‑1 drugs.

How Does Rapid Weight Loss Affect Bone Strength?

Rapid weight loss reduces the mechanical load on bones, which can weaken them over time. Dr. Horneff compared this effect to astronauts returning from space with lower bone density due to a lack of gravitational force.

When the body suddenly weighs less, bones don’t receive the same signals to maintain strength. This can lead to decreased bone mass, especially if weight loss is extreme or happens quickly. For people using GLP‑1 medications, this is one of the most overlooked GLP‑1 side effects.

What Other Bone‑Related Risks Are Emerging in Research?

The new findings align with earlier studies showing a link between GLP‑1 drugs and osteoporosis‑related fractures in older adults with Type 2 diabetes. The FDA already lists “increased risk of bone fracture in older adults and women” on semaglutide’s official label. Researchers are still investigating whether the risk comes from the drug itself or from the weight loss it causes.

Some experts believe the mechanism is multifactorial, involving hormonal shifts, nutrient deficiencies, and changes in bone metabolism. While more research is needed, the pattern is becoming harder to ignore.

What Symptoms Should Users Watch For?

Osteoporosis is often called a “silent disease” because it develops without noticeable symptoms. Many people don’t realize they have it until they suffer a fracture from a minor fall or even simple movements. Warning signs may include:

Back pain
Shrinking height
Posture changes

However, these symptoms often appear late. Because GLP‑1 side effects can mask or mimic early symptoms, users may overlook subtle changes. Regular bone‑density screenings can help detect problems before they become serious.

How Can GLP‑1 Users Protect Their Bone Health?

Experts recommend incorporating weight‑bearing exercise, such as walking or strength training, to stimulate bone growth. Ensuring adequate intake of calcium and vitamin D (through diet or supplements) may also help offset GLP‑1 side effects.

Patients should discuss bone‑health monitoring with their healthcare provider, especially if they are older, menopausal, or losing weight rapidly. Slower dose escalation may reduce appetite suppression and nutrient loss.

Staying Informed Helps You Stay Protected

The new research doesn’t mean people should abandon GLP‑1 medications, but it does highlight the importance of understanding their full impact. A 30% increase in a silent bone‑health risk is something users, especially older adults and women, should take seriously. By staying aware of GLP‑1 side effects, monitoring bone health, and making smart lifestyle choices, patients can protect themselves while still benefiting from these powerful medications.